0001739614-24-000013.txt : 20240312 0001739614-24-000013.hdr.sgml : 20240312 20240312180443 ACCESSION NUMBER: 0001739614-24-000013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eckelman Brendan P. CENTRAL INDEX KEY: 0001766433 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39452 FILM NUMBER: 24743796 MAIL ADDRESS: STREET 1: C/O INHIBRX, INC. STREET 2: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibrx, Inc. CENTRAL INDEX KEY: 0001739614 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824257312 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 4 1 wk-form4_1710281074.xml FORM 4 X0508 4 2024-03-08 0 0001739614 Inhibrx, Inc. INBX 0001766433 Eckelman Brendan P. C/O INHIBRX, INC. 11025 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037 0 1 0 0 Chief Scientific Officer 0 Stock Option (right to buy) 33.63 2024-03-08 4 M 0 2150 35.75 D 2021-01-15 Common Stock 2150 37850 D Stock Option (right to buy) 33.63 2024-03-11 4 M 0 6877 35.3004 D 2021-01-15 Common Stock 6877 30973 D Stock Option (right to buy) 23.30 2024-03-11 4 M 0 6681 35.3339 D 2033-01-03 Common Stock 6681 33319 D Stock Option (right to buy) 33.63 2024-03-12 4 M 0 19898 35.2547 D 2021-01-15 Common Stock 19898 11075 D Stock Option (right to buy) 23.30 2024-03-12 4 M 0 4152 35.2503 D 2033-01-03 Common Stock 4152 29167 D Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. The stock options were exercised in multiple transactions at prices ranging from $35.2927 to $35.3104, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. The stock options were exercised in multiple transactions at prices ranging from $35.25 to $35.325, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The stock options were exercised in multiple transactions at prices ranging from $35.25 to $35.27, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. /s/ Kelly D. Deck, as attorney in fact for Brendan P. Eckelman 2024-03-12